Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy
Condition(s):Renal Cell Carcinoma, Clear Cell, SomaticLast Updated:March 19, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Renal Cell Carcinoma, Clear Cell, SomaticLast Updated:March 19, 2024Recruiting
Condition(s):Renal AngiomyolipomaLast Updated:November 18, 2023Recruiting
Condition(s):EpilepsyLast Updated:November 14, 2022Recruiting
Condition(s):Gallbladder CancerLast Updated:April 27, 2023Recruiting
Condition(s):MeningiomaLast Updated:November 13, 2023Not yet recruiting
Condition(s):Colon CancerLast Updated:March 8, 2024Not yet recruiting
Condition(s):High Grade Glioma; Diffuse Intrinsic Pontine Glioma; Anaplastic Astrocytoma; Glioblastoma; Glioblastoma Multiforme; Diffuse Midline Glioma, H3 K27M-Mutant; Metastatic Brain Tumor; WHO Grade III Glioma; WHO Grade IV GliomaLast Updated:November 22, 2023Not yet recruiting
Condition(s):Kidney Transplant Failure and RejectionLast Updated:May 12, 2023Recruiting
Condition(s):Solid Tumor, Adult; Hepatocellular CarcinomaLast Updated:February 28, 2023Recruiting
Condition(s):Renal Cell CarcinomaLast Updated:November 18, 2021Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.